Halozyme Therapeutics, Inc. (NASDAQ:HALO) Forecasted to Earn Q3 2025 Earnings of $1.01 Per Share

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Analysts at Zacks Research raised their Q3 2025 earnings estimates for Halozyme Therapeutics in a note issued to investors on Monday, April 22nd. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will earn $1.01 per share for the quarter, up from their prior forecast of $0.98. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.45 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ FY2025 earnings at $3.92 EPS and Q1 2026 earnings at $1.21 EPS.

Several other brokerages also recently weighed in on HALO. TheStreet downgraded shares of Halozyme Therapeutics from a “b-” rating to a “c+” rating in a report on Monday, January 22nd. StockNews.com raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. TD Cowen initiated coverage on shares of Halozyme Therapeutics in a research note on Thursday, February 29th. They issued an “outperform” rating and a $54.00 price target on the stock. The Goldman Sachs Group dropped their price target on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a research note on Thursday, January 18th. Finally, JMP Securities restated a “market outperform” rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, February 21st. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $53.29.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $39.12 on Tuesday. The firm has a market capitalization of $4.97 billion, a P/E ratio of 18.54, a PEG ratio of 0.45 and a beta of 1.25. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89. The company has a 50 day moving average price of $39.71 and a 200 day moving average price of $37.79. Halozyme Therapeutics has a 52 week low of $29.85 and a 52 week high of $45.00.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). The firm had revenue of $230.04 million for the quarter, compared to analysts’ expectations of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%.

Institutional Investors Weigh In On Halozyme Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rise Advisors LLC purchased a new stake in Halozyme Therapeutics in the first quarter valued at approximately $25,000. Principal Securities Inc. purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter worth approximately $34,000. First Horizon Advisors Inc. raised its stake in shares of Halozyme Therapeutics by 24.5% during the fourth quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 293 shares during the last quarter. Parkside Financial Bank & Trust purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter worth approximately $64,000. Finally, Headlands Technologies LLC raised its stake in shares of Halozyme Therapeutics by 1,068.2% during the fourth quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 1,613 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total value of $416,400.00. Following the completion of the transaction, the senior vice president now directly owns 156,558 shares of the company’s stock, valued at approximately $6,519,075.12. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders sold 30,000 shares of company stock valued at $1,196,800. 2.40% of the stock is currently owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.